HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.

Abstract
The goal of this study was to develop pharmacogenomic predictors in response to standard chemotherapy drugs in breast cancer cell lines and test their predictive value in patients who received treatment with the same drugs. Nineteen human breast cancer cell lines were tested for sensitivity to paclitaxel (T), 5-fluorouracil (F), doxorubicin (A) and cyclophosphamide (C) in vitro. Baseline gene expression data were obtained for each cell line with Affymetrix U133A gene chips, and multigene predictors of sensitivity were derived for each drug separately. These predictors were applied individually and in combination to human gene expression data generated with the same Affymetrix platform from fine needle aspiration specimens of 133 stage I-III breast cancers. Tumor samples were obtained at baseline, and each patient received 6 months of preoperative TFAC chemotherapy followed by surgery. Cell line-derived prediction results were correlated with the observed pathologic response to chemotherapy. Statistically robust differentially expressed genes between sensitive and resistant cells could only be found for paclitaxel. False discovery rates associated with the informative genes were high for all other drugs. For each drug, the top 100 differentially expressed genes were combined into a drug-specific response predictor. When these cell line-based predictors were applied to patient data, there was no significant correlation between observed response and predicted response either for individual drug predictors or combined predictions. Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients.
AuthorsCornelia Liedtke, Jing Wang, Attila Tordai, William F Symmans, Gabriel N Hortobagyi, Ludwig Kiesel, Kenneth Hess, Keith A Baggerly, Kevin R Coombes, Lajos Pusztai
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 121 Issue 2 Pg. 301-9 (Jun 2010) ISSN: 1573-7217 [Electronic] Netherlands
PMID19603265 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Doxorubicin
  • Cyclophosphamide
  • Paclitaxel
  • Fluorouracil
Topics
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Biomarkers, Tumor (genetics)
  • Breast Neoplasms (drug therapy, genetics, pathology)
  • Cell Line, Tumor
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Drug Resistance, Neoplasm (genetics)
  • Female
  • Fluorouracil (administration & dosage)
  • Gene Expression Profiling (methods)
  • Humans
  • Neoplasm Staging
  • Oligonucleotide Array Sequence Analysis
  • Paclitaxel (administration & dosage)
  • Predictive Value of Tests
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: